Status:
TERMINATED
Schizophrenic Patients in Integrated Care
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of the study is to investigate the well-being of schizophrenic patients treated with quetiapine XR combined with participation in the integrated care program compared to a treatment with q...
Eligibility Criteria
Inclusion
- Patients with baseline SWN-K \<=70
- Provision of signed informed consent
- Out-patients with schizophrenia, schizophreniform disorder or schizoaffective disorder, severe postpartum depressive disorders with psychotic symptoms and a minimum HAM-D cut off score of 20 points
Exclusion
- Evidence of a clinical relevant disease, eg renal or hepatic impairment, significant coronary heart disease, hepatitis B or C, AIDS
- Patients with known cardiovascular disease or other condition predisposing to hypotension or family history of QT prolongation
- Patients who pose an imminent risk of suicide or danger to self or others
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT00681629
Start Date
July 1 2008
End Date
November 1 2008
Last Update
July 30 2012
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
München, Bavaria, Germany
2
Research Site
Oranienburg, Brandenburg, Germany
3
Research Site
Hamburg, Hamburg, Germany
4
Research Site
Lüneburg, Lower Saxony, Germany